Meta-Analysis of Traditional Chinese Medicine for Postoperative Ovarian Cancer

A systematic review and meta-analysis synthesizing results from 22 randomized controlled trials (n=1719) published between January 2018 and June 2025. The study, authored by Yuyang Mi and shared on figshare, evaluates the efficacy of adjuvant Traditional Chinese Medicine in reducing chemotherapy toxicity and improving immune function in postoperative ovarian cancer patients.

Use Cases

• Assessing the impact of Traditional Chinese Medicine on chemotherapy-related adverse events based on the reported risk ratios.
• Analyzing changes in immune cell subsets (CD3+, CD4+, CD4+/CD8+ ratio) from integrative therapy trials.
• Evaluating improvements in patient performance status based on Karnofsky Performance Status (KPS) scores.
• Conducting secondary meta-analyses on the efficacy of integrative oncology treatments.

Strengths

• Analysis is based on 22 randomized controlled trials involving 1719 patients.
• Includes specific quantitative results such as risk ratios and mean differences with 95% confidence intervals.
• Has a registered systematic review protocol (CRD420251242407).

Limitations

• The dataset is a 15.2 KB DOCX document; the underlying trial data is not provided in a structured, machine-readable format.
• The description notes limitations in study quality and heterogeneity among the included trials.
• Row count and column-level documentation for any underlying data are unknown.

Provenance

Source

figshare, author Yuyang Mi.

Collection Method

Systematic literature search across six databases (CNKI, Wanfang, VIP, SinoMed, PubMed, Cochrane Library).

Time Range

Literature published from January 2018 to June 2025.

Freshness

Last updated 2026-04-30 05:25:03.

Geography

Studies likely focus on Chinese populations, given the databases searched, but the description does not explicitly state geographic scope.